» Articles » PMID: 25579746

Immunogenetics of Type 1 Diabetes Mellitus

Overview
Journal Mol Aspects Med
Date 2015 Jan 13
PMID 25579746
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune disease arising through a complex interaction of both genetic and immunologic factors. Similar to the majority of autoimmune diseases, T1DM usually has a relapsing remitting disease course with autoantibody and T cellular responses to islet autoantigens, which precede the clinical onset of the disease process. The immunological diagnosis of autoimmune diseases relies primarily on the detection of autoantibodies in the serum of T1DM patients. Although their pathogenic significance remains uncertain, they have the practical advantage of serving as surrogate biomarkers for predicting the clinical onset of T1DM. Type 1 diabetes is a polygenic disease with a small number of genes having large effects (i.e. HLA), and a large number of genes having small effects. Risk of T1DM progression is conferred by specific HLA DR/DQ alleles [e.g., DRB1*03-DQB1*0201 (DR3) or DRB1*04-DQB1*0302 (DR4)]. In addition, HLA alleles such as DQB1*0602 are associated with dominant protection from T1DM in multiple populations. A discordance rate of greater than 50% between monozygotic twins indicates a potential involvement of environmental factors on disease development. Viral infections may play a role in the chain of events leading to disease, albeit conclusive evidence linking infections with T1DM remains to be firmly established. Two syndromes have been described in which an immune-mediated form of diabetes occurs as the result of a single gene defect. These syndromes are termed autoimmune polyglandular syndrome type I (APS-I) or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), and X-linked poyendocrinopathy, immune dysfunction and diarrhea (XPID). These two syndromes are unique models to understand the mechanisms involved in the loss of tolerance to self-antigens in autoimmune diabetes and its associated organ-specific autoimmune disorders. A growing number of animal models of these diseases have greatly helped elucidate the immunologic mechanisms leading to autoimmune diabetes.

Citing Articles

Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.

Foster T, Bruggeman B, Haller M Drugs. 2025; .

PMID: 39873914 DOI: 10.1007/s40265-025-02150-8.


Advances in Type 1 Diabetes Mellitus Management in Children.

Bahal M, Pande V, Dua J, Mane S Cureus. 2024; 16(8):e67377.

PMID: 39310514 PMC: 11416143. DOI: 10.7759/cureus.67377.


Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities.

Zhidu S, Ying T, Rui J, Chao Z Stem Cell Res Ther. 2024; 15(1):266.

PMID: 39183341 PMC: 11346273. DOI: 10.1186/s13287-024-03885-z.


Small RNA-Seq and real time rt-qPCR reveal islet miRNA released under stress conditions.

Aljani B, Lindner A, Weigelt M, Zhao M, Sharma V, Bonifacio E Islets. 2024; 16(1):2392343.

PMID: 39154325 PMC: 11332650. DOI: 10.1080/19382014.2024.2392343.


and Enteroviruses as Synergistic Triggers of Type 1 Diabetes Mellitus.

Root-Bernstein R, Chiles K, Huber J, Ziehl A, Turke M, Pietrowicz M Int J Mol Sci. 2023; 24(9).

PMID: 37176044 PMC: 10179352. DOI: 10.3390/ijms24098336.


References
1.
Zhang L, Crawford F, Yu L, Michels A, Nakayama M, Davidson H . Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes. Proc Natl Acad Sci U S A. 2014; 111(7):2656-61. PMC: 3932899. DOI: 10.1073/pnas.1323436111. View

2.
Stadinski B, Delong T, Reisdorph N, Reisdorph R, Powell R, Armstrong M . Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol. 2010; 11(3):225-31. PMC: 3166626. DOI: 10.1038/ni.1844. View

3.
Awata T, Kurihara S, Iitaka M, Takei S, Inoue I, Ishii C . Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. Diabetes. 1998; 47(1):128-9. DOI: 10.2337/diab.47.1.128. View

4.
Wijesekara N, Chimienti F, Wheeler M . Zinc, a regulator of islet function and glucose homeostasis. Diabetes Obes Metab. 2009; 11 Suppl 4:202-14. DOI: 10.1111/j.1463-1326.2009.01110.x. View

5.
Wilson S, Kent S, Patton K, Orban T, Jackson R, EXLEY M . Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998; 391(6663):177-81. DOI: 10.1038/34419. View